🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Thank you & congratulations to COVIDSurg collaborators for contributing to The Lancet publication: 🔓thelancet.com/journals/lance… Surgical outcomes in patients with perioperative SARS-CoV-2: > Pulmonary complication (PPC) rate 51% > 30-day mortality 24% > 82% deaths associated PPC

Best cameo ! Thanks for taking the time to send well wishes to all our residents ... amazing !

An opportunity for students to hear about the Univ of Toronto Urology program, to meet our selection committee and talk with some of our amazing residents!

Who wrote this incredible “paper”? Your Public Health Service will not go unnoticed 😂

limited health care resource remains to be a significant bottle neck that we are (somehow) no better prepared to face two years into the pandemic.... as the waitlists grow many more of our patients will suffer

Instead of focusing blame on the few anti-vaxxers among us (some of whom are victims of misinformation), instead ask why investments have not been made for our system to be more resilient and higher quality at all times. In past years even flu season brought us to our knees

Unfortunate case with fortunate outcome! Just published: replantation for penile glans amputation during neonatal circumcision Armando J. Lorenzo sciencedirect.com/science/articl…

Could statins improve survival in men with advanced PC? Our meta-analysis suggests a consistent protective OS and CCS signal in ~120,000 pts Statins are cheap, safe, and have an established CVD benefit. Time for an RCT! Rob Hamilton Laurence Klotz neil fleshner Univ of Toronto Urology

Canadian Urology residents take on Society of Urologic Oncology YUO meeting in San Diego 🇨🇦🇨🇦

Thanks to Rob Hamilton for his mentorship, paper coming soon. More evidence to support a reduction in the use of adjuvant chemotherapy following pRPLND for PSII disease. Poster here:

Feel privileged to present our meta-analysis of clinical studies comparing TFL vs Ho:YAG lasers for lithotripsy at #AUA23. Thanks to Dr. Chua, Armando J. Lorenzo and Jason Lee for their mentorship and the opportunity! Check out our manuscript here: doi.org/10.1111/bju.15…

Big paper out in The Lancet Oncology from my partner Alex Zlotta highlighting data for TMT in #mibc thelancet.com/journals/lanon… Univ of Toronto Urology U of T Department of Surgery Sinai Health

Thrilled to have matched to the Toronto SUO Oncology fellowship! The opportunity to continue learning from invaluable mentors in a city that I love, alongside people that I love is a blessing Univ of Toronto Urology Society of Urologic Oncology YUO

Check out our latest publication comparing open vs. robo RPLND. Our findings suggest R-RPLND is associated with: 🔹Shorter LOS (1 vs. 5 days) 🔹Lower EBL (200ml) 🔹Comparable relapse and complication rates Rob Hamilton European Urology Oncology sciencedirect.com/science/articl…

Minimizing the use of chemotherapy following pRPLND, the Princess Margaret Cancer Centre experience: bjui-journals.onlinelibrary.wiley.com/doi/full/10.11… Rob Hamilton

Most pts with pathologic stage II testicular non-seminomatous germ cell tumors treated with #primaryRPLND only won't experience relapse or need chemo. Altho #adjuvantchemotherapy may reduce relapse risk, disease specific survival is unchanged #testescancer doi.org/10.1111/bju.16…

As therapies evolve and men with advanced prostate cancer live longer, screening for adverse effects associated with androgen deprivation should become a priority. Our study in Cancer revealing low rates of testing across the board. Christopher Wallis (he/him/his) ICES

This population-based assessment in Ontario, Canada revealed that only 11.9% of patients w/ #ProstateCancer on ADT received all recommended testing to screen for adverse effects associated with treatment. acsjournals.onlinelibrary.wiley.com/doi/full/10.10… Ahmad Mousa OncoAlert #GU25

Chemotherapy, radiation, and their combination increase the risk of non-germ cell secondary malignancies after testicular cancer treatment. Our systematic review & meta-analysis out now in JNCI. Rob Hamilton academic.oup.com/jnci/advance-a…

This systematic review and meta-analysis found that radiation, chemotherapy, and their combination were associated with an increased risk of secondary malignancies after treatment of testicular germ cell tumors, while surgery alone was not. Ahmad Mousa oxford.ly/441X2m0